Research

Alexander Bick, MD, PhD, and colleagues are studying inflammation at the single-cell level in the rare disease RUNX1-FPD.

Chan Zuckerberg Initiative grant supports single-cell study of rare inherited disease

A multidisciplinary team led by Vanderbilt University Medical Center investigator Alexander Bick, MD, PhD, has been awarded a $2 million, four-year grant to study inflammation at the single-cell level in the rare disease RUNX1-FPD.

Study may lead to new diabetes, heart disease treatments

Vanderbilt research found that deletion of an autophagy-participating factor named PIK3C3 from the fat cells of mice led to compromised body temperature control, abnormal blood lipid levels, fatty liver and diabetes.

Roden honored for his leadership in precision medicine

Vanderbilt’s Dan Roden, MD, will receive the PMWC 2023 Pioneer Award Jan. 27 during this year’s Precision Medicine World Conference.

Anti-nausea drug response in children

Genetic variation in a metabolic enzyme was not associated with response to the anti-nausea drug odansetron in children, Vanderbilt researchers report.

Novel lung cancer biomarker

Autoantibodies against the p53 tumor suppressor protein may be a novel biomarker for identifying people, especially African Americans, at high risk for lung cancer.

Early effects of Huntington disease

Impairments in brain executive function happen earlier than motor symptoms in people with the gene mutation that causes Huntington disease, suggesting younger ages and cognitive symptoms be considered for any future clinical trials.

1 38 39 40 41 42 135